Streetbeat News

Analyst Ratings

ABNB

Citigroup analyst Ronald Josey maintains a Buy rating on Airbnb (NASDAQ:ABNB) and raises the price target from $135 to $160.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2023 | 11:34 am

UPST

Barclays analyst Ramsey El-Assal maintains an Equal-Weight rating on Upstart Holdings (NASDAQ:UPST) and raises the price target from $17 to $31.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2023 | 11:29 am

TDG

Barclays analyst David Strauss maintains an Overweight rating on TransDigm Gr (NYSE:TDG) and raises the price target from $930 to $1040.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2023 | 11:27 am

SUN

Barclays analyst Theresa Chen has maintained an Overweight rating on Sunoco (NYSE:SUN) but lowered the price target from $51 to $50.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2023 | 11:25 am

RPAY

Barclays analyst Ramsey El-Assal maintains an Overweight rating on Repay Hldgs (NASDAQ:RPAY) and raises the price target from $9 to $11.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2023 | 11:24 am

AAPL

BTCUSD

TSLA

Over the weekend, several stories made headlines including ethical accusations against Jared Kushner over a Saudi investment deal, Tesla's Cybertruck facing another breakdown during testing, North Korea's surprising military appointment, Nassim Nicholas Taleb's warning on Bitcoin, and Apple's plans for a significant upgrade for the tenth-anniversary edition of its smartwatch.

Portfolio Pulse from Benzinga Neuro

August 14, 2023 | 11:24 am

PX

Barclays analyst Benjamin Budish maintains an Overweight rating on P10 (NYSE:PX) and raises the price target from $14 to $15.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2023 | 11:23 am

MQ

Barclays analyst Ramsey El-Assal has maintained an Overweight rating on Marqeta (NASDAQ:MQ) and raised the price target from $6 to $7.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2023 | 11:22 am

KGS

Barclays analyst Theresa Chen maintains an Equal-Weight rating on Kodiak Gas Services (NYSE:KGS) and raises the price target from $19 to $22.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2023 | 11:20 am

GANX

Chardan Capital analyst Keay Nakae has reiterated a 'Buy' rating on Gain Therapeutics (NASDAQ:GANX) and maintained a $6 price target.

Portfolio Pulse from richadhand@benzinga.com

August 14, 2023 | 11:17 am